LP-471756
CAS No. 413605-11-5
LP-471756( —— )
Catalog No. M34320 CAS No. 413605-11-5
LP-471756 is a specific antagonist of GPR139 and inhibits LP-360924-stimulated cAMP production (IC50 = 640 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 39 | Get Quote |
|
| 10MG | 62 | Get Quote |
|
| 25MG | 126 | Get Quote |
|
| 50MG | 205 | Get Quote |
|
| 100MG | 322 | Get Quote |
|
| 200MG | 455 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLP-471756
-
NoteResearch use only, not for human use.
-
Brief DescriptionLP-471756 is a specific antagonist of GPR139 and inhibits LP-360924-stimulated cAMP production (IC50 = 640 nM).
-
DescriptionLP-471756 is a potent GPR139 antagonist with an IC50 value of 640 nM. LP-471756 inhibits LP-360924-stimulated cAMP production.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetGPR
-
RecptorGPR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number413605-11-5
-
Formula Weight329.46
-
Molecular FormulaC19H23NO2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (758.82 mM; Ultrasonic )
-
SMILESCc1ccccc1NS(=O)(=O)c1ccc(cc1)C1CCCCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Vedel L, et al. Pharmacology and function of the orphan GPR139 G protein-coupled receptor. Basic Clin Pharmacol Toxicol. 2020 Jun;126 Suppl 6(Suppl 6):35-46.?
molnova catalog
related products
-
P2Y2R/GPR17 antagoni...
P2Y2R/GPR17 antagonist 1 (Compound 14m) is a dual antagonist with an IC50 of 3.17 μM for P2Y2R and 1.67 μM for GPR17.
-
GPR40/FFAR1 modulato...
GPR40/FFAR1 modulator 1 is an agonist and an allosteric modulator for Gq-coupled free fatty acid receptor 1 (GPR40/FFAR1).
-
Myristyl nicotinate
Myristyl nicotinate is an ester prodrug being developed for delivery of nicotinic acid (NIC) into the skin for prevention of actinic keratosis and its progression to skin cancer.
Cart
sales@molnova.com